Silexion Therapeutics Expands SIL204 Development Plan

Silexion Therapeutics ( (SLXN) ) has issued an update.

On March 28, 2025, Silexion Therapeutics announced an expanded development plan for its siRNA candidate, SIL204, following promising preclinical data. The plan includes a dual-route administration strategy to treat KRAS-driven pancreatic cancer, integrating systemic and intratumoral delivery methods. This approach aims to address the aggressive nature of KRAS-driven cancers, characterized by high mortality and limited treatment options. Building on previous clinical results, Silexion plans further studies and regulatory submissions in 2025 and 2026, potentially advancing SIL204 into the next stage of clinical development.

More about Silexion Therapeutics

Silexion Therapeutics Corp is a clinical-stage company focused on developing proprietary treatments for KRAS-driven cancers using its siRNA platform technology. The company aims to silence oncogenes and prevent the production of mutated KRAS proteins that drive cancer growth. Silexion’s first-generation product, siG12DLoder, has shown promising results in Phase 2 clinical trials, and the company is now advancing its second-generation siRNA candidate, SIL204, which targets various KRAS mutations.

YTD Price Performance: -40.70%

Average Trading Volume: 14,286,954

Technical Sentiment Signal: Buy

Current Market Cap: $9.93M

See more insights into SLXN stock on TipRanks’ Stock Analysis page.